SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing significant discussion following reports that Nvidia has paused evaluating its 18A chipmaking process, a crucial element of Intel's revitalized foundry strategy. However, much of the community is highly skeptical, calling the news old or manipulative, and arguing that 18A was primarily for internal use while future external foundry deals, potentially including Nvidia, are centered on the more advanced 14A node. Many investors express frustration over perceived short-term price suppression, yet maintain long-term confidence in Intel's competitive positioning.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending following the successful orbital launch of its BlueBird 6 satellite, which is touted as the largest commercial communications array ever deployed in low Earth orbit. This achievement is fueling significant bullish sentiment, with many anticipating the validation of its direct-to-device cellular broadband vision and rapid network expansion. However, discussions also reflect skepticism around the company's long-term profitability and current valuation, even as the community focuses on future scaling and execution milestones.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros (OMER) is experiencing extreme volatility and intense investor focus as the market eagerly awaits an imminent FDA PDUFA decision for its life-saving drug, Narsoplimab, to treat TA-TMA. Following a trading halt for news pending, community sentiment is largely optimistic for approval, anticipating a significant price surge fueled by high short interest and the drug's first-in-class status for a condition with no existing treatment. The broader context of the recent de-risking deal with Novo Nordisk and previous regulatory hurdles fuels speculation of substantial long-term value and even a potential buyout, making this a pivotal moment for the company.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending amidst intensified speculation for a major partnership or buyout, catalyzed by a recent acquisition in the biotech sector and heightened discussions around its undervalued protein-based vaccine platform and combination influenza/COVID candidate. Shareholders are openly frustrated with management's perceived inaction and lack of communication, echoing an activist investor's push for a strategic review to unlock value from Novavax's differentiated non-mRNA technology, especially as concerns about mRNA vaccine safety grow. This confluence of factors, coupled with high short interest, positions the company for potentially significant market movement should a transformative deal be announced.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax Technologies is a major talking point as Sanofi announced its acquisition for $15.50 per share, valuing the company at $2.2 billion and representing a substantial premium. This move integrates Dynavax's marketed adult Hepatitis B vaccine, its shingles candidate, and a recently licensed oral COVID-19 vaccine program into Sanofi's global immunization portfolio. While many long-term shareholders are relieved to see a resolution, a significant portion of the community feels the acquisition price undervalues the company's assets and growth prospects.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is trending as the market assesses its recently completed Marigold acquisition and updated strong guidance for future financial performance. Community discussions highlight optimism for its advanced AI platform and proprietary data in the evolving marketing sector, with many anticipating significant upside following its participation in an upcoming key industry event. Despite some short-term price fluctuations, investors are closely watching for its potential re-rating as an an undervalued AI-driven marketing powerhouse.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath (PATH) is experiencing significant positive momentum, driven by its upcoming inclusion in the S&P MidCap 400 index, effective early next year. The community views this as a major catalyst for structural demand, anticipating increased institutional buying, enhanced liquidity, and greater visibility for the Agentic AI and automation leader.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Agios Pharmaceuticals Inc

Agios Pharmaceuticals is trending following the FDA's expanded approval of AQVESME (mitapivat) for adults with alpha- or beta-thalassemia, establishing it as the first and only oral treatment for this condition. The community is actively discussing the commercial implications and the drug's high cost, while also reflecting on broader concerns about management's communication style and historical execution.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is heavily trending amid widespread speculation of an imminent buyout, fueled by recent significant insider purchases and strong financial fundamentals including growing Lupkynis sales and a robust cash position. The community is actively discussing the potential Phase 2 indications for AUR200, while many shareholders voice frustration over perceived management opacity and repeatedly call for a change in leadership to unlock further value.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

iShares Silver Trust is surging to new all-time highs, driven by intensifying industrial demand from rapidly expanding sectors like AI data centers, EVs, and solar, alongside significant global supply concerns. The rally is further fueled by China's impending export restrictions on silver, with market participants eagerly discussing a potential 'silver squeeze' and a fundamental re-evaluation of its value, though some anticipate a near-term correction after its rapid ascent.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Instacart acquired Eversight in 2022 whose AI-powered software allows retailers to test customized pricing and promotions directly with their individual customers.</li><li>The company said on Monday that while retail partners will continue to set their own prices on Instacart and they may choose to vary the price of items on a store-by-store basis, Instacart will not support any item price testing services.&nbsp;</li><li>The company also said that the pricing tests were not dynamic pricing or surveillance pricing and added that they were never based on supply or demand, personal data, demographics, or individual shopping behavior.</li></ul> Instacart (<a href="https://stocktwits.com/symbol/CART">CART</a>) said on Monday that retailers will no longer be able to use artificial intelligence-driven pricing tests on its grocery delivery platform after it drew flak from customers and the federal trade commission.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.instacart.com/company/updates/ending-item-price-tests-on-instacart">said</a> that retailers will no longer be able to use Eversight technology to run item price tests on Instacart. Instacart acquired Eversight in 2022 whose AI-powered software allows retailers to test customized pricing and promotions directly with their individual customers. According to Instacart, several retailers rely on Eversight to optimize pricing including The Giant Company, Schnucks, and Kroger. Grocers who used Eversight have recorded revenue growth of 1-3%, according to the company.However, this caused shoppers to pay different prices for identical items from the same store.“We understand that the tests we ran with a small number of retail partners that resulted in different prices for the same item at the same store missed the mark for some customers. At a time when families are working exceptionally hard to stretch every grocery dollar, those tests raised concerns, leaving some people questioning the prices they see on Instacart. That’s not okay,” Instacart said. “Now, if two families are shopping for the same items, at the same time, from the same store location on Instacart, they see the same prices — period.”<h2 class="st-heading-2">New Pricing Rules</h2>Instacart said on Monday that while retail partners will continue to set their own prices on Instacart and they may choose to vary the price of items on a store-by-store basis, Instacart will not support any item price testing services.“We’ll continue working closely with partners to remove markups where possible and better align their online prices with their in-store prices,” the company said.The company also said that the pricing tests were not dynamic pricing or surveillance pricing and added that they were never based on supply or demand, personal data, demographics, or individual shopping behavior.<h2 class="st-heading-2">Eversight Draws Flak</h2>Earlier this month, Consumer Reports <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.consumerreports.org/money/questionable-business-practices/instacart-ai-pricing-experiment-inflating-grocery-bills-a1142182490/#:~:text=Many%20U.S.%20shoppers%20who%20order,Sprouts%20Farmers%20Market%2C%20and%20Target.">noted</a> that the AI-enabled pricing experiments on Instacart caused price differences of as much as 23% for identical products from one customer to the next. The report also said that Instacart’s algorithmic pricing experiments were found to be occurring through the platform at several of the nation’s biggest grocery retailers, including Albertsons, Costco, Kroger, Safeway, Sprouts Farmers Market, and Target.Following the investigation by Consumer Reports, Reuters <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/legal/litigation/ftc-investigating-instacarts-ai-pricing-tool-source-says-2025-12-17/">reported</a> that the U.S. Federal Trade Commission is probing Instacart and seeking information about its Eversight pricing tool. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>CART shares traded 2% lower at the time of writing. On Stocktwits, retail sentiment around CART stayed within the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.CART stock has risen 8% this year and by about 6.5% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/dogwood-therapeutics-interim-trial-results-in-chemotherapy-induced-pain-fail-to-boost-investor-confidence/cLeF8WPREMu">DWTX Stock Heads For Worst Day In 9 Months As Chemotherapy Pain Drug Interim Study Data Fails To Boost Investor Confidence</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

 (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Instacart Pulls Plug On AI-Driven Grocery Pricing Tests After Shopper Backlash And Regulatory Scrutiny

The company said that retailers will no longer be able to use Eversight technology to run item price tests on Instacart.

Equity

The company said that retailers will no longer be able to use Eversight technology to run item price tests on Instacart.


<ul class="summary-bullets"><li>Deal signals continued demand for space and defense technology as firms look to beef up their offerings.</li><li>CACI said it expects to realize a tax benefit with a present value of $225 million.</li><li>Donald Trump recently signed a record $901 billion defense bill for the U.S.</li></ul>CACI International (CACI) on Monday announced it has agreed to acquire ARKA Group in an all-cash deal valued at $2.6 billion, from funds managed by Blackstone Tactical Opportunities, to expand its offerings in the national security and space sectors.&nbsp;The transaction is expected to close in the third quarter of fiscal year 2026, the statement said.&nbsp;The all-cash deal signals continued demand for space and defense technology as firms look to beef up their offerings in this sector amid ongoing global conflicts and rising geopolitical tensions in Asia and Europe, prompting nations to increase defense spending.The deal will help CACI add ARKA’s space-based sensor systems and ground-based software processing products to its portfolio.CACI said it expects to realize a tax benefit with a present value of $225 million and noted that the ARKA transaction is expected to close in the third quarter of fiscal year 2026.“The acquisition of ARKA positions CACI to capture significant future opportunities in the space domain across the Intelligence Community, U.S. Space Force, and other Department of War customers,” said John Mengucci, CACI President and Chief Executive Officer. &nbsp;<h2 class="st-heading-2">Demand For Defense Tech</h2>The demand for defense and intelligence contracts has been on the rise as countries look to beef up their defense capabilities amid rising global tensions among several nations.The U.S. Congress recently passed a record $901 billion defense bill, later signed by Donald Trump, that included a pay raise for troops and security aid to Ukraine. It also included funding for Trump’s “golden dome” missile defense system.Global military spending is projected to hit $2.56 trillion in 2025, more than $420 billion higher than the level before the outbreak of the war in Ukraine, according to a<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.janes.com/osint-insights/open-source-intelligence-webinars/2025-defence-budgets-annual-report"> report</a> from Janes, an open-source data provider for defense intelligence.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2><a href="https://stocktwits.com/symbol/RKLB">CACI International shares</a> were up nearly 1% in Monday’s pre-market trade. Retail sentiment on Stocktwits around the company trended in the ‘bullish’ territory at the time of writing.&nbsp;<figure class="image"><img style="aspect-ratio:793/93;" src="https://news.stocktwits-cdn.com/caci_PNG_cd6d6bca25.webp" alt="Retail sentiment on Stocktwits around the company trended in the ‘bullish’ territory." width="793" height="93"></figure>CACI shares have gained over 35% this year.Get updates to this developing story <a href="https://stocktwits.com/news-articles/markets/equity/caci-international-to-acquire-arka-from-blackstone-funds-in-2-6-b-cash-deal/cLeF0pSREM4">directly on Stocktwits</a>.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nvidia-h200-ai-chips-china-exports-february-2026/cLeFLp7REMd">Nvidia May Resume H200 AI Chip Exports To China In February, Days After Trump Administration Begins Policy Review: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 The U.S. headquarters of CACI International Inc. is seen May 12, 2004 in Arlington, Virginia. (Photo by Mark Wilson/Getty Images)

What’s Behind CACI’s $2.6B Acquisition of ARKA?

ARKA Group offers space-based sensor technology and optical technology that will enable CACI to expand its offerings

ARKA Group offers space-based sensor technology and optical technology that will enable CACI to expand its offerings. 


<ul class="summary-bullets"><li>Disc Medicine management said earlier this month that its application seeking approval for Bitopertin has officially been accepted for review on schedule.&nbsp;</li><li>Wall Street analysts dismissed the media report hinting at approval delays and termed the share drop as overblown.&nbsp;</li><li>Disc Medicine is hopeful for an approval of the drug by the end of January 2026.</li></ul>Shares of Disc Medicine (<a href="https://stocktwits.com/symbol/IRON">IRON</a>) plunged 12% on Friday after a report flagged concerns pertaining to the U.S. Food and Drug Administration’s speedy approval of the company’s blood disorder drug Bitopertin.Disk Medicine’s Biopertin for the treatment of Erythropoietic Protoporphyria (EPP) is one of the 18 drugs to currently have been tapped for fast review by the FDA under its Commissioner's National Priority Voucher program. The Commissioner's National Priority Voucher program, announced in June, aims to reduce FDA assessment times to one to two months from the standard 10 to 12 months.However, Stat News <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.statnews.com/2025/12/19/fda-voucher-program-political-interference/">reported</a> on Friday, citing government officials, that high-level FDA officials have been involved in every part of the new program involving the vouchers. The political pressure is creating “uncomfortable situations” for career scientists at the FDA, the report said.The report dragged down investor sentiment and hopes for an expedited approval of Bitopertin as the report also noted that FDA senior official Vinay Prasad raised doubts about the drug’s effectiveness.<h2 class="st-heading-2">Wall Street Dismisses Concerns</h2>Jefferies analyst Roger Song, however, termed the share drop a “stock overreaction”. Song said that while the priority voucher program's timeline may be under pressure with increasing demand, the firm remains confident on Bitopertin's approval in EPP under the program, based on robust efficacy and safety data and to-date review experience.TD Cowen also maintained its ‘Buy’ rating on the shares and said the firm believes skepticism on the program’s path is overblown. Disc's management remains confident, it noted, and added that the firm's confidence in accelerated approval remains high.BMO Capital said that it had discussions with Disc Medicine’s management which highlighted a lack of interactions with senior official Prasad but robust active dialogue with the FDA. While Prasad may have speculated efficacy concerns related to Bitopertin, these have not been communicated to Disc, and no clear concerning questions around efficacy have been raised, BMO added. Some procedural questions have been asked by FDA in trying to understand the Bitopertin data package and how it may translate to clinical benefit, it said. The firm has an ‘Outperform’ rating on the shares with a price target of $120.<h2 class="st-heading-2">Management Takeaway</h2>Disc Medicine management said earlier this month that its application seeking approval for Bitopertin has officially been accepted for review on schedule and expressed hopes for potential launch by the end of January 2026, consistent with the 1-2 month timeline for drugs which receive the priority voucher.“Our commercialization efforts have been accelerated significantly and we are well on our way to launch readiness,” the company said.The company submitted its application for approval in patients aged 12 years and older with EPP on September 29. Erythropoietic Protoporphyria (EPP) is a rare, inherited metabolic disorder causing extreme sensitivity to sunlight (phototoxicity), leading to immediate, painful skin reactions like burning, tingling, redness, and swelling, due to the buildup of protoporphyrin in red blood cells from an enzyme deficiency.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around IRON stayed within the ‘bearish’ territory while message volume rose from ‘low’ to ‘high’ levels.IRON stock has gained about 26% this year.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/nvidia-intel-shares-jump-after-us-antitrust-agencies-clear-5-billion-deal/cLe0d1gREtc">Nvidia, Intel Shares Jump After US Antitrust Agencies Clear $5B Deal That Deepens Their Chip Partnership</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Disc Medicine logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Disc Medicine Stock Slides After FDA Fast-Track Approval Doubts Surface — Wall Street Calls It An ‘Overreaction’

Stat News on Friday raised concerns for Biopertin’s expedited approval under the FDA Commissioner's National Priority Voucher program. 

<ul class="summary-bullets"><li>The Idaho office of the U.S. Department of Energy has granted the Preliminary Documented Safety Analysis for the firm’s Aurora Fuel Fabrication Facility.</li><li>The next step would be to obtain a Documented Safety Analysis (DSA), the third document that would provide an update on the facility's final design and construction.&nbsp;</li><li>Oklo is on the list of companies selected for the DOE’s nuclear pilot programs.&nbsp;</li></ul>Oklo Inc. (OKLO) announced on Tuesday that the U.S. Department of Energy’s (DOE) Idaho office has given an initial safety approval for its Aurora Fuel Fabrication Facility, effectively granting permission to start facility assembly.The DOE’s Idaho Operations Office has granted the nuclear technology company the Preliminary Documented Safety Analysis (PDSA) for Aurora, the first facility approved under the DOE’s Fuel Line Pilot Program, the company said.The PDSA is the second out of three safety documents for the facility’s approval. Oklo said that the next step would be a Documented Safety Analysis (DSA), an update about the final design and construction of the facility.<h2 class="st-heading-2">DOE Nuclear Pilot Programs</h2>Earlier this year, the DOE launched new pilot programs to hasten the development of advanced nuclear reactors and domestic fuel following Executive Orders from President Donald Trump to streamline national laboratory processes for reactor testing.As part of this, the DOE issued a Request for Application (RFA) seeking U.S. reactor companies to construct and operate test reactors outside of the national laboratories with DOE authorization. Oklo is among the companies selected for the program. The Aurora facility will combine fuel production and power delivery to enable the commercial deployment of nuclear energy.“By advancing modern fuel fabrication and recycling, we’re addressing fuel-supply constraints, improving the economics of our powerhouses, and opening new long-term revenue streams for the business,” Oklo’s co-founder and CEO, Jacob DeWitte, said. “We’re moving swiftly toward full deployment of this fuel facility where we will repurpose fuel from the legacy Experimental Breeder Reactor-II (EBR-II) for use in Oklo’s Aurora-INL.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, the retail sentiment around <a href="https://stocktwits.com/symbol/OKLO">OKLO</a> remained ‘bearish’ over a week, and message volume climbed to ‘normal’ from ‘low’ levels at the time of writing.<figure class="image"><img style="aspect-ratio:1298/148;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_16_at_5_32_35_PM_png_589c7406cd.webp" alt="On Stocktwits, the retail sentiment around OKLO remained ‘bearish’ over a week, and message volume climbed to ‘normal’ from ‘low’ levels at the time of writing." width="1298" height="148"></figure>Shares of OKLO were down 0.28% in Tuesday’s pre-market at the time of writing and have surged over 345% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

In this photo illustration, a person holds a smartphone displaying the logo of Oklo Inc.

Oklo Gets Initial Safety Approval From DOE For Aurora Facility To Begin Assembly 

Aurora is the first facility approved under the DOE’s Fuel Line Pilot Program, the company announced on Tuesday. 

<ul class="summary-bullets"><li>The company now intends to request a re-examination of the opinion which would be undertaken by a different set of reviewers that conduct a new examination.</li><li>Anavex submitted an application to the EMA for Blarcamesine in November 2024.</li></ul>Shares of Anavex Life Sciences Corp. (AVXL) fell 3% after hours on Friday after the company said that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a negative opinion on its application seeking approval for the drug Blarcamesine in treating Alzheimer’s disease.In November, Anavex <a href="https://stocktwits.com/news-articles/markets/equity/avxl-shares-slump-pre-market-after-ema-committee-fails-to-recommend-approval-for-alzheimers-drug/cLPQ7tkRE4E">said </a>it was informed by the CHMP of a negative trend vote on its application for Blarcamesine following its oral explanation in a session held behind closed doors on Nov. 11. The company was awaiting a formal opinion from the committee.<h2 class="st-heading-2">Negative Opinion ‘As Expected’</h2>Anavex <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.anavex.com/post/anavex-life-sciences-provides-update-on-regulatory-review-in-the-eu-for-blarcamesine-to-treat-early">said</a> on Friday that the CHMP has indeed adopted a negative opinion “as expected.” CHMP provides recommendations to the EMA on human medicines, which the agency uses to approve or reject a drug. The lack of a positive recommendation dampens chances for an EMA approval for the drug.The company now intends to request a re-examination of the opinion which would be undertaken by a different set of reviewers that conduct a new examination, independent from the first opinion.Anavex submitted an application to the EMA for Blarcamesine in November 2024 based on data from a Phase 2b/3 trial, and the agency subsequently accepted it in December. If the application is approved, it would allow Blarcamesine to be marketed in all EU member states.Besides Alzheimer’s, Anavex is also studying Blarcamesine in treating Parkinson's disease dementia and Rett syndrome.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around AVXL stock rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.A Stocktwits user opined that this is the best time for big pharma players “to throw bone for this company” provided the low share price and “promising assets.”&nbsp;<stembedurl>https://stocktwits.com/lookupdownside/message/639061239</stembedurl><a href="https://stocktwits.com/symbol/AVXL">AVXL stock</a> is down 63% this year and by 52% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/oracle-denies-data-center-delay-report-after-shares-slide-on-openai-build-out-concerns/cLICt16RE8O">Oracle Denies Data Center Delay Report After Shares Slide On OpenAI Build-Out Concerns</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

Anavex Stock Slides After Hours On EMA Panel’s Negative Alzheimer’s Drug Opinion — Retail Traders Talk Buyout Potential

Anavex said on Friday that the CHMP has indeed adopted a negative opinion “as expected.”

<ul class="summary-bullets"><li>Sarepta is set to exchange 1.25% convertible senior notes due 2027 for new 4.875% convertible senior notes due 2030, alongside about $31.6 million in cash.</li><li>The transaction is slated to be completed around Dec. 18, 2025.&nbsp;</li><li>The deal would involve the purchase of approximately 691,000 SRPT common stock, the company said.&nbsp;</li></ul>Sarepta Therapeutics Inc. (SRPT) shares tumbled more than 6% on Thursday after the company announced a debt refinancing plan totaling about $291 million.&nbsp;The drug manufacturer said that, as per the privately negotiated agreements, it would exchange $291.4 million of 1.25% convertible senior notes due 2027 for the same amount of new 4.875% convertible senior notes due 2030 alongside about $31.6 million in cash.The deal is expected to close around Dec. 18, 2025.&nbsp;<h2 class="st-heading-2">Deal Details</h2>After the debt refinancing, the aggregate principal amount of SRPT’s 4.875% convertible senior notes due 2030 will be approximately $893.4 million. This would result in $158.6 million in aggregate principal amount of the existing notes to remain outstanding under the previous terms, the company said.&nbsp;The transaction would also entail the sale by the private parties of approximately 691,000 shares of the company’s common stock,&nbsp;which could affect the market price of the company’s shares and notes, the firm noted. Since the deal is private, none of the new notes and shares issuable upon conversion are registered for public sale.Most recently,&nbsp;<a href="https://stocktwits.com/symbol/SRPT/">SRPT</a> issued an equity grant of about $12 million to Douglas S. Ingram, its chief executive officer. In November, the company also received FDA approval to begin a new study to test the impact of immunosuppressant sirolimus on liver injury in non-ambulatory Duchenne patients.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, SRPT was among the top 10 trending stocks on Thursday morning. The retail sentiment around SRPT jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume climbed to ‘normal’ from ‘low’ levels at the time of writing.<figure class="image"><img style="aspect-ratio:1290/150;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_11_at_8_56_01_PM_png_5f8dc3f44e.webp" alt="SRPT stock sentiment and message volume." width="1290" height="150"></figure>Shares of SRPT are down over 83% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

POLAND - 2025/01/25: In this photo illustration, the Sarepta Therapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Why Is SRPT Stock Falling Today?

Sarepta Therapeutics announced a debt refinancing plan totaling about $291 million. 

In this photo illustration, a person holds a smartphone displaying the logo of Rocket Lab USA Inc.

Rocket Lab Is Finally Having Its SpaceX Moment — Yet One Grounded Project Could Make Or Break This Year’s Fantastic Surge

When compared to the first quarter of 2021, Rocket Lab’s recent quarter reported a revenue surge of 750%, making the third quarter of this year its best one ever.

<ul class="summary-bullets"><li>SAIC's third-quarter adjusted earnings per share of $2.58 beat analyst estimates of $2.06.&nbsp;</li><li>Revenue for the quarter came in line with estimates at $1.87 billion.&nbsp;</li><li>The company also raised its adjusted diluted EPS guidance to $9.80 to $10.00, up from $9.40 to $9.60 earlier.</li></ul>Science Applications International Corporation (SAIC) shares traded over 16% higher on Thursday following upbeat third-quarter results and improved guidance.The defense and technology company posted adjusted earnings per share (EPS) of $2.58, far beating the analyst consensus of $2.06, according to Fiscal.ai data. Revenue for the quarter was $1.87 billion, in line with estimates, although 6% lower than the same period last year.SAIC also raised its adjusted earnings before interest, tax, depreciation and amortization (EBITDA) guidance to about $695 million, up from between $680 million and $690 million previously. It is also projecting adjusted diluted EPS of $9.80 to $10.00, up from $9.40 to $9.60 reported before."Our third quarter results reflect a 5.6% revenue contraction, slightly ahead of our guidance when adjusting for the approximate 1% headwind from the government shutdown, and strong margins due to continued sound program execution,” said Jim Reagan, SAIC Interim Chief Executive Officer, in the statement.<h2 class="st-heading-2">Against The Odds</h2>SAIC’s stellar performance comes despite the recent government shutdown, which has affected several federal contractors this quarter. About 98% of the company’s total revenues come from government contracts or subcontracts, the company had said earlier in a filing.Its operating income as a percentage of revenues decreased in the quarter compared with the same period last year, which it attributed to executive transition costs related to a contract termination.SAIC also acquired SilverEdge Government Solutions, a provider of technology solutions and products, last month. The company said that the deal enhanced its strategy to provide mission-focused, IP-based solutions and commercial products to its customers.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment surrounding the stock shifted to ‘extremely bullish’ from ‘neutral’ while message volume jumped to ‘extremely high’.<figure class="image"><img style="aspect-ratio:1276/158;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_04_at_9_01_20_PM_png_3582235eb8.webp" alt="Stocktwits retail sentiment shifted to ‘extremely bullish’ from ‘neutral’ and message volume jumped to ‘extremely high’." width="1276" height="158"></figure> SAIC shares have lost over 9% this year.Also Read: <a href="https://stocktwits.com/news-articles/markets/equity/wedbush-backs-snowflake-after-q3-print-suggests-buying-the-dip/cLILyrXRESt">Wedbush Backs Snowflake After Q3 Print, Suggests Buying The Dip</a>For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

AeroVironment exhibited during the Defense Expo Korea 2022, held at KINTEX (Korea International Exhibition and Convention Center) on September 21, 2022 in Goyang city, Gyeonggi, South Korea.  (Photo by Chris Jung/NurPhoto via Getty Images)

SAIC Stock Surges Post Upbeat Q3 Earnings, Improved Guidance

The defense and tech company’s adjusted earnings per share of $2.58 beat analyst estimates by over $0.50. 

<ul class="summary-bullets"><li>Redemplo was approved by the FDA earlier this month, marking a milestone for Arrowhead as it becomes a commercial-stage company.</li><li>The company said it sees a “decent chance” that its new Redemplo trials will show statistical significance in treating patients at high risk of pancreatitis.</li><li>Arrowhead reported revenue of $829.4 million in fiscal year 2025, compared to $3.55 million in FY24.</li></ul> Morgan Stanley on Wednesday raised its price target on Arrowhead Pharmaceuticals (ARWR) to $48 from $45 while keeping an ‘Equal Weight’ rating on the shares.Shares of the company traded 22% higher at the time of writing on Wednesday morning.According to TheFly, the analyst noted that Redemplo's approval in familial chylomicronemia syndrome last week "importantly sets the stage for meaningful label expansion into SHTG (severe hypertriglyceridemia)." Severe hypertriglyceridemia refers to a medical condition where there are dangerously high levels of triglycerides in the blood.<h2 class="st-heading-2">Significance Of Redemplo Approval</h2>Redemplo is Arrowhead’s first FDA-approved medicine. Its approval earlier this month as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome marked a milestone for Arrowhead as it evolves into a commercial-stage pharmaceutical company.Familial chylomicronemia syndrome (FCS) is a rare, genetic disorder where the body cannot properly break down fat, leading to extremely high levels of triglycerides in the blood. Arrowhead estimates that about 6,500 people in the U.S. are living with FCS.“Arrowhead is truly just getting started, and we are well-positioned to execute on our aggressive goals in discovery, clinical development, business development, and commercial to enable multiple potential new launches, both independently and with partners, over the coming years,” Arrowhead CEO Christopher Anzalone said on Tuesday.The company also said it sees a “decent chance” that its new Redemplo trials will show statistical significance in treating patients at high risk of pancreatitis due to high triglyceride levels.<h2 class="st-heading-2">FY25 Earnings</h2>Arrowhead <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://arrowheadpharma.com/news-press/arrowhead-pharmaceuticals-reports-2025-fiscal-year-end-results/">reported</a> revenue of $829.4 million in fiscal 2025 (FY25), compared to $3.6 million in FY24, and above an analyst estimate of $757.44 million.Net loss per share came in at $0.01, down from the loss of $5 reported in FY24, and lower than an analyst estimate of a loss of $0.03 per share.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around ARWR jumped from 'bullish' to 'extremely bullish' territory over the past 24 hours, while message volume remained at 'high' levels.<a href="https://stocktwits.com/symbol/ARWR">ARWR stock</a> has more than tripled this year and risen by about 172% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/li-auto-posts-unexpected-loss-in-q3-as-ev-sales-drop/cL53uOfREWq">Li Auto Posts Unexpected Loss In Q3 As EV Sales Drop</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Arrowhead Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Arrowhead Pharmaceuticals Stock Jumps 22% After Morgan Stanley Hikes Price Target

According to TheFly, the analyst noted that Redemplo's approval in familial chylomicronemia syndrome last week "importantly sets the stage for meaningful label expansion into SHTG (severe hypertriglyceridemia)."

<ul class="summary-bullets"><li>The company said its net loss for the three months through the end of September was $0.11 per share, down from a loss of $0.14 per share in the corresponding quarter of 2024.</li><li>The company is now seeking a re-examination of CHMP’s opinion on its Alzheimer’s drug, Blarcamesine.&nbsp;</li><li>It expects a cash runway of more than 3 years.</li></ul> Shares of Anavex Life Sciences Corp. (AVXL) jumped 10% on Monday afternoon after the company reported a lower-than-expected loss for the fourth quarter.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.anavex.com/post/anavex-life-sciences-reports-fiscal-2025-fourth-quarter-financial-results-and-provides-business-upd">said</a> that net loss in the three months through the end of September was $0.11 per share, down from a loss of $0.14 per share in the corresponding quarter of 2024, and lower than the loss of $0.15 per share expected by analysts, according to data from Fiscal AI.The company ended the quarter with cash and cash equivalents of $102.6 million. It now expects a cash runway of more than 3 years.<h2 class="st-heading-2">Blarcamesine’s Path Forward</h2>Anavex is focused on developing treatments for neurodegenerative disorders like Alzheimer’s. “There are currently an estimated 7.2 million people living with Alzheimer’s disease in the U.S. and 7 million in Europe, respectively. We continue to be focused on orally, targeted upstream medicines, particularly in the context of early Alzheimer’s disease,” said CEO Christopher U. Missling.Earlier this month, Anavex<a href="https://stocktwits.com/news-articles/markets/equity/avxl-shares-slump-pre-market-after-ema-committee-fails-to-recommend-approval-for-alzheimers-drug/cLPQ7tkRE4E"> said</a> that a European Medicines Agency (EMA) committee did not recommend approval of the company’s application for its Alzheimer’s drug, Blarcamesine. The Committee for Medicinal Products for Human Use provides recommendations to the EMA on human medicines, which the agency uses to approve or reject a drug. The lack of a positive recommendation dampens the chances of EMA approval for the drug.The committee is expected to adopt a formal opinion on the application at its December meeting, the company said, while adding that it intends to request a re-examination of the committee’s opinion. The firm reiterated the course of action on Tuesday.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around AVXL stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.A Stocktwits user opined that they are “cautiously optimistic” about the stock’s future.<stembedurl>https://stocktwits.com/Filldagap/message/637414773</stembedurl>AVXL stock is down 68% this year and by 63% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/pmcb-stock-jumps-after-company-sells-stake-in-femasys/cL52o2lREgL">PMCB Stock Jumps 25% After Company Sells Stake In Femasys</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

 In this photo illustration, an Anavex Life Sciences Corp. logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

AVXL Stock Jumps On Lower Q4 Loss, Anticipation For EMA Approval Of Alzheimer’s Drug

Anavex ended the quarter with cash and cash equivalents of $102.6 million.

EAOR
iShares ESG Aware 60/40 Balanced Allocation ETF

Feed

News

Sentiment

Fundamentals

Info

Latest EAOR News

EAORiShares ESG Aware 60/40 Balanced Allocation ETF